Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CareDx, Inc. before investing.

In this article, we go over a few key elements for understanding CareDx, Inc.’s stock price such as:

• CareDx, Inc.’s current stock price and volume
• Why CareDx, Inc.’s stock price changed recently
• Upgrades and downgrades for CDNA from analysts
• CDNA’s stock price momentum as measured by its relative strength

About CareDx, Inc. (CDNA)

Before we jump into CareDx, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Want to learn more about CareDx, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CareDx, Inc..

CareDx, Inc.’s Stock Price as of Market Close

As of June 12, 2026, 4:00 PM, CST, CareDx, Inc.’s stock price was $22.970.

CareDx, Inc. is down 2.92% from its previous closing price of $23.660.

During the last market session, CareDx, Inc.’s stock traded between $22.780 and $23.770. Currently, there are approximately 51.15 million shares outstanding for CareDx, Inc..

CareDx, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

CareDx, Inc. Stock Price History

CareDx, Inc.’s (CDNA) price is currently up 0.66% so far this month.

During the month of June, CareDx, Inc.’s stock price has reached a high of $24.130 and a low of $21.580.

Over the last year, CareDx, Inc. has hit prices as high as $24.130 and as low as $10.960. Year to date, CareDx, Inc.’s stock is up 21.92%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused CareDx, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 12, 2026, there were 0 analysts who downgraded CareDx, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate CareDx, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CareDx, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

CareDx, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CareDx, Inc. (CDNA) by visiting AAII Stock Evaluator.

Relative Price Strength of CareDx, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 12, 2026, CareDx, Inc. has a weighted four-quarter relative price strength of 6.98%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how CareDx, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CareDx, Inc. Stock Price: Bottom Line

As of June 12, 2026, CareDx, Inc.’s stock price is $22.970, which is down 2.92% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CareDx, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.